Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapolsertib - Menarini

Next Previous
Drug Profile

Dapolsertib - Menarini

Alternative Names: MEN 1703; MEN1703/SEL24; SEL 24; SEL24 program; SEL24-1; SEL24-B489; SEL24/MEN1703

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selvita
  • Developer Menarini; Ryvu Therapeutics; Theradex
  • Class Antineoplastics; Benzimidazoles; Halogenated hydrocarbons; Nitro compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma
  • Preclinical Myelofibrosis

Most Recent Events

  • 25 Apr 2025 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in France (PO) (NCT06534437) (Ryvu Therapeutics pipeline, May 2025)
  • 25 Apr 2025 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in Spain (PO) (NCT06534437) (Ryvu Therapeutics pipeline, May 2025)
  • 25 Apr 2025 Phase-II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, Monotherapy) in France (PO) (NCT06534437) (Ryvu Therapeutics pipeline, May 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top